Combating antimicrobial resistance: policy recommendations to save lives.
作者信息
Spellberg Brad, Blaser Martin, Guidos Robert J, Boucher Helen W, Bradley John S, Eisenstein Barry I, Gerding Dale, Lynfield Ruth, Reller L Barth, Rex John, Schwartz David, Septimus Edward, Tenover Fred C, Gilbert David N
出版信息
Clin Infect Dis. 2011 May;52 Suppl 5(Suppl 5):S397-428. doi: 10.1093/cid/cir153.
Abstract
摘要
相似文献
1
Combating antimicrobial resistance: policy recommendations to save lives.抗击抗菌素耐药性：拯救生命的政策建议。
Clin Infect Dis. 2011 May;52 Suppl 5(Suppl 5):S397-428. doi: 10.1093/cid/cir153.
2
Antimicrobial resistance: action by laboratories today for a cure tomorrow.抗微生物药物耐药性：今日实验室采取行动，明日实现治愈。
Indian J Med Microbiol. 2011 Jul-Sep;29(3):205-6. doi: 10.4103/0255-0857.83899.
3
Antimicrobial stewardship education for medical students.面向医学生的抗菌药物管理教育。
Clin Infect Dis. 2013 Nov;57(9):1366. doi: 10.1093/cid/cit480. Epub 2013 Jul 26.
4
Towards a rational antimicrobial testing policy in the laboratory.迈向实验室合理的抗菌药物检测政策。
Indian J Med Microbiol. 2011 Jul-Sep;29(3):209-12. doi: 10.4103/0255-0857.83901.
5
Strengthening surveillance key to addressing antimicrobial resistance.加强监测是应对抗菌药物耐药性的关键。
Indian J Med Microbiol. 2016 Oct-Dec;34(4):413-415. doi: 10.4103/0255-0857.195378.
6
Intra-abdominal infections: model of antibiotic stewardship in an era with limited antimicrobial options.腹腔内感染：抗菌药物选择有限时代的抗生素管理模式
Int J Antimicrob Agents. 2011 Sep;38(3):271-2. doi: 10.1016/j.ijantimicag.2011.06.003. Epub 2011 Jul 22.
7
Combating antimicrobial resistance: antimicrobial stewardship program in Taiwan.应对抗微生物药物耐药性：台湾的抗微生物药物管理计划。
J Microbiol Immunol Infect. 2012 Apr;45(2):79-89. doi: 10.1016/j.jmii.2012.03.007. Epub 2012 Apr 5.
8
Overcoming Antibiotic Resistance.克服抗生素耐药性。
Cell Host Microbe. 2019 Jul 10;26(1):8-11. doi: 10.1016/j.chom.2019.06.007.
9
Outpatient antibiotic use in the United States: time to "get smarter".美国门诊抗生素的使用：是时候“变得更明智”了。
Clin Infect Dis. 2011 Oct;53(7):640-3. doi: 10.1093/cid/cir449.
10
Microbial resistance to antimicrobial drugs.微生物对抗菌药物的耐药性。
Can Vet J. 1998 Jun;39(6):329-31.
引用本文的文献
1
Fluorinated Rh(I)-NHC Compounds as Potential Antibacterials Against Multidrug-Resistant Clinical Isolates Producing ESBL.氟化铑（I）-氮杂环卡宾化合物作为针对产生超广谱β-内酰胺酶的多重耐药临床分离株的潜在抗菌剂。
Pharmaceutics. 2025 Jul 28;17(8):973. doi: 10.3390/pharmaceutics17080973.
2
Interpretable prediction on treatment response of piperacillin-tazobactam for lower respiratory tract infections using machine learning.使用机器学习对哌拉西林-他唑巴坦治疗下呼吸道感染的反应进行可解释预测。
Medicine (Baltimore). 2025 Aug 1;104(31):e43460. doi: 10.1097/MD.0000000000043460.
3
The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents.抗生素治疗的不断变化格局：在新型药物时代重新评估治疗时长。
Antibiotics (Basel). 2025 Jul 20;14(7):727. doi: 10.3390/antibiotics14070727.
4
Surveillance for Health Care-Associated Infections, Antimicrobial Resistant Organisms and Antimicrobial use in Canadian Long-Term Care Homes: A Cross-Sectional Survey.加拿大长期护理机构中医疗保健相关感染、抗菌药物耐药菌及抗菌药物使用情况的监测：一项横断面调查
J Assoc Med Microbiol Infect Dis Can. 2025 May 29;10(2):160-170. doi: 10.3138/jammi-2024-0019. eCollection 2025 Jun.
5
Uniting disciplines against antimicrobial resistance (AMR): highlights from a multidisciplinary inaugural AMR summit.联合多学科对抗抗菌药物耐药性（AMR）：首届多学科AMR峰会亮点
Antimicrob Steward Healthc Epidemiol. 2025 Jul 11;5(1):e149. doi: 10.1017/ash.2025.10039. eCollection 2025.
6
Antibacterial and Antibiofilm Activities of Hydralazine, an Antihypertensive Drug: In Vitro and In Silico Approaches.降压药肼苯哒嗪的抗菌和抗生物膜活性：体外和计算机模拟方法
Antibiotics (Basel). 2025 Mar 10;14(3):286. doi: 10.3390/antibiotics14030286.
7
The prevalence and distribution of aminoglycoside resistance genes.氨基糖苷类耐药基因的流行情况与分布
Biosaf Health. 2023 Jan 6;5(1):14-20. doi: 10.1016/j.bsheal.2023.01.001. eCollection 2023 Feb.
8
Utility of Artificial Intelligence in Antibiotic Development: Accelerating Discovery in the Age of Resistance.人工智能在抗生素研发中的应用：在耐药时代加速发现进程
Cureus. 2025 Jan 31;17(1):e78296. doi: 10.7759/cureus.78296. eCollection 2025 Jan.
9
Insights into kinetic and regression models developed to estimate the abundance of antibiotic-resistant genes during biological digestion of wastewater sludge.关于在废水污泥生物消化过程中为估算抗生素抗性基因丰度而开发的动力学和回归模型的见解。
J Water Health. 2025 Feb;23(2):238-259. doi: 10.2166/wh.2025.372. Epub 2025 Jan 22.
10
Antimicrobial Susceptibility Profiles of Commensal spp. Isolates from Turkeys in Hungarian Poultry Farms Between 2022 and 2023.2022年至2023年匈牙利家禽养殖场火鸡共生菌分离株的抗菌药敏谱
Antibiotics (Basel). 2025 Feb 14;14(2):200. doi: 10.3390/antibiotics14020200.
本文引用的文献
1
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.社区获得性细菌性肺炎抗菌药物临床试验设计
Clin Investig (Lond). 2011 Jan 1;1(1):19-32. doi: 10.4155/cli.10.1.
2
An unmet medical need: rapid molecular diagnostics tests for respiratory tract infections.一项未满足的医疗需求：用于呼吸道感染的快速分子诊断检测
Clin Infect Dis. 2011 May;52 Suppl 4:S384-95. doi: 10.1093/cid/cir055.
3
Development of new antibacterials: a laudable aim, but what is the value?新型抗菌药物的研发：一个值得称赞的目标，但价值何在？
Clin Infect Dis. 2010 Sep 15;51(6):752-3; author reply 754-5. doi: 10.1086/655956.
4
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.印度、巴基斯坦和英国出现新的抗生素耐药机制：一项分子、生物学和流行病学研究。
Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.
5
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.21世纪的国家癌症临床试验系统：重振美国国立癌症研究所合作组计划。
J Natl Cancer Inst. 2010 Sep 8;102(17):1371. doi: 10.1093/jnci/djq291. Epub 2010 Aug 3.
6
Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population.社区中产超广谱β-内酰胺酶大肠埃希菌的出现和传播：来自偏远和受控人群研究的经验教训。
J Infect Dis. 2010 Aug 15;202(4):515-23. doi: 10.1086/654883.
7
Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎抗菌药物未来临床试验的推荐设计特点。
Clin Infect Dis. 2010 Aug 1;51 Suppl 1(Suppl 1):S150-70. doi: 10.1086/653065.
8
Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.产超广谱β-内酰胺酶大肠埃希菌引起的社区获得性菌血症的危险因素和治疗结局。
Int J Antimicrob Agents. 2010 Sep;36(3):284-7. doi: 10.1016/j.ijantimicag.2010.05.009. Epub 2010 Jun 30.
9
Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010.检出携带金属β-内酰胺酶的肠杆菌科分离株-美国，2010 年。
MMWR Morb Mortal Wkly Rep. 2010 Jun 25;59(24):750.
10
Cancer clinical trials--a chronic but curable crisis.癌症临床试验——一场长期但可治愈的危机。
N Engl J Med. 2010 Jul 22;363(4):306-9. doi: 10.1056/NEJMp1005843. Epub 2010 Jun 16.
Zotero 插件